OCULAR THERAPEUTIX, INC 8-K

What Happened

• Ocular Therapeutix (OCUL) filed an 8-K (Item 5.02) reporting that on January 20, 2026 CFO and COO Donald Notman began a temporary medical leave. The Board appointed Jason Robins, the company’s Senior Vice President, Finance, as interim Chief Financial Officer and the company’s principal financial and accounting officer effective January 20, 2026. Mr. Robins will serve in the interim role until Mr. Notman’s anticipated return.

Key Details

• Interim appointment effective: January 20, 2026.
• Interim appointee: Jason Robins, age 49; Senior VP, Finance since January 2025; prior VP, Finance at Fusion Pharmaceuticals (Oct 2020–Dec 2024).
• Equity grant: option to purchase 33,000 shares at $11.45 per share (Nasdaq closing price on Jan 20, 2026); vests monthly in equal installments over 4 years. Potential exercise proceeds = $377,850 (33,000 × $11.45) if fully exercised.
• Corporate paperwork: Mr. Robins entered the Company’s standard indemnification agreement; no related-party transactions or special arrangements reported.

Why It Matters

• Leadership continuity: The company has designated an internal, finance-focused interim CFO to maintain financial reporting, controls, and day-to-day finance operations while the CFO is on leave.
• Compensation and alignment: The stock option grant aligns the interim CFO’s incentives with shareholders and may result in modest dilution if exercised.
• Governance and disclosures: The change is material for investors monitoring executive stability and the individuals responsible for financial statements and SEC filings.